Peptide conjugate
A platelet substitute which does not induce formation of unnecessary thrombi and intravascular coagulation of blood, by causing aggregation of resting platelets in the blood vessel, and has a specific aggregation action is provided. It was found as a result that a peptide conjugate, in which a synthesized form of a dodecapeptide contained in the GPIIb/IIIa recognizing site of fibrinogen is bound to a micro particle, has a property to bind specifically to only substantially activated GPIIb/IIIa, which is preferable as a platelet substitute, thereby accomplishing the present invention.
1 . A conjugate which is a formula:
(micro particle)-[(linker)-Cys-His-His-Leu-Gly-
Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val-COOH] n ,
or a formula:
(micro particle)-[(spacer)-(Iinker)-Cys-His-His-
Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val-COOH] n ,
wherein n is an integer.
2 . The conjugate according to claim 1 , wherein the micro particle is selected from the group consisting of a vesicle, a micelle, a protein polymer and a synthetic polymer.
3 . The conjugate according to claim 1 , wherein the micro particle is selected from the group consisting of a vesicle, a recombinant albumin polymer, a latex particle and a biodegradable polymer.
4 . The conjugate according to claim 1 , wherein the micro particle has a particle diameter of 50 nm or more.
5 . The conjugate according to claim 1 , wherein the micro particle has a particle diameter of 10 μm or less.
6 . The conjugate according to claim 1 , wherein the linker is a compound in which its one terminal reacts with an SH group, and another terminal reacts with any one of an OH group, a COOH group and an NH 2 group.
7 . The conjugate according to claim 1 , wherein the linker is selected from the group consisting of dicarboxylic acid, aminocarboxylic acid, a bismaleimide compound, a bishalocarbonyl compound, a halocarbonylmaleimide compound, dithiomaleimide, dithiocarboxylic acid and maleimidecarboxylic acid.
8 . The conjugate according to claim 1 , wherein the linker is selected from the group consisting of dicarboxylic acid, aminocarboxylic acid, a bismaleimide compound, a bishalocarbonyl compound, a halocarbonylmaleimide compound, dithiomaleimide, dithiocarboxylic acid and maleimidecarboxylic acid, and has a carbon chain of C2-10.
9 . The conjugate according to claim 1 , wherein the spacer is one or at least two combination selected from the group consisting of polyoxyethylene, a polypeptide, a polysaccharide, albumin and an antibody.
10 . The conjugate according to claim 1 , wherein the micro particle is a latex particle, the spacer is albumin and the linker is dithiocarboxylic acid.
11 . The conjugate according to claim 1 , wherein the micro particle is a vesicle, the spacer is polyethylene glycol and the linker is maleimidecarboxylic acid.
12 . The conjugate according to claim 1 which is a platelet substitute.
13 . A method for controlling platelet aggregation, which comprises administering to a subject in need thereof an effective amount of the conjugate according to claim 1 .
14 . A process for producing the conjugate according to claim 1 , which comprises binding the micro particle to the formula:
Cys-His-His-Leu-Gly-Gly-Ala-Lys-Gln-Ala-Gly-Asp-Val-COOH] n ,
wherein n is an integer
via the liner or the spacer-linker.
15 . A diagnostic agent or reagent which comprises the conjugate according to claim 1 .
16 . The diagnostic agent or reagent according to claim 15 , which is a diagnostic agent for platelet dysfunction, a biological or medical reagent, a platelet aggregation inhibitor, a reagent for screening an anti-thrombus agent, or a diagnostic or therapeutic agent for inspecting a vascular injury region and a thrombus formation region.
17 . A drug carrier which comprises the conjugate according to claim 1 .
18 . The drug carrier which comprises the conjugate according to claim 17 , wherein the drug is selected from the group consisting of a hemostatic agent, a vasoconstrictor agent, an anti-inflammatory agent, an anti-blood coagulation agent and an anti-platelet agent.
19 . A pharmaceutical composition which comprises the conjugate according to claim 1 .
20 . The pharmaceutical composition according to claim 19 , which comprises a drug selected from the group consisting of a hemostatic agent, a vasoconstrictor agent, an anti-inflammatory agent, an anti-blood coagulation agent and an anti-platelet agent.
21 . The pharmaceutical composition according to claim 19 , which is useful for preventing or treating vascular disorder, vascular injury and thrombosis.